142 related articles for article (PubMed ID: 14563529)
1. DNA strand breaks induced by the anti-topoisomerase II bis-dioxopiperazine ICRF-193.
Hajji N; Pastor N; Mateos S; Domínguez I; Cortés F
Mutat Res; 2003 Sep; 530(1-2):35-46. PubMed ID: 14563529
[TBL] [Abstract][Full Text] [Related]
2. Evidence from studies with intact mammalian cells that merbarone and bis(dioxopiperazine)s are topoisomerase II poisons.
Snyder RD
Drug Chem Toxicol; 2003 Feb; 26(1):15-22. PubMed ID: 12643037
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of genotoxic effects of anti-topoisomerase II drugs ICRF-193 and bufalin in Chinese hamster ovary cells.
Pastor N; Domínguez I; Mateos S; Cortés F
Mutat Res; 2002 Mar; 515(1-2):171-80. PubMed ID: 11909765
[TBL] [Abstract][Full Text] [Related]
4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
5. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
6. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
Snyder RD
Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Kizaki H; Onishi Y
Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II poisoning by ICRF-193.
Huang KC; Gao H; Yamasaki EF; Grabowski DR; Liu S; Shen LL; Chan KK; Ganapathi R; Snapka RM
J Biol Chem; 2001 Nov; 276(48):44488-94. PubMed ID: 11577077
[TBL] [Abstract][Full Text] [Related]
9. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay.
Godard T; Deslandes E; Sichel F; Poul JM; Gauduchon P
Mutat Res; 2002 Sep; 520(1-2):47-56. PubMed ID: 12297143
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of topoisomerase II by ICRF-193, the meso isomer of 2,3-bis(2,6-dioxopiperazin-4-yl)butane. Critical dependence on 2,3-butanediyl linker absolute configuration.
Snapka RM; Woo SH; Blokhin AV; Witiak DT
Biochem Pharmacol; 1996 Aug; 52(4):543-9. PubMed ID: 8759026
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T
Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205
[TBL] [Abstract][Full Text] [Related]
13. Effects of an inhibitor of topoisomerase II, ICRF-193 on the formation of ultraviolet-induced chromosomal aberrations.
Ikushima T; Shima Y; Ishii Y
Mutat Res; 1998 Aug; 404(1-2):35-8. PubMed ID: 9729258
[TBL] [Abstract][Full Text] [Related]
14. Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange.
Hamatake M; Andoh T; Ishida R
Anticancer Drugs; 1997 Jul; 8(6):637-42. PubMed ID: 9300580
[TBL] [Abstract][Full Text] [Related]
15. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Jones NJ; Ellard S; Waters R; Parry EM
Carcinogenesis; 1993 Dec; 14(12):2487-94. PubMed ID: 8269616
[TBL] [Abstract][Full Text] [Related]
16. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Tanabe K; Ikegami Y; Ishida R; Andoh T
Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the cell-killing mechanism of the topoisomerase II-targeting drug ICRF-193.
Oestergaard VH; Knudsen BR; Andersen AH
J Biol Chem; 2004 Jul; 279(27):28100-5. PubMed ID: 15123716
[TBL] [Abstract][Full Text] [Related]
19. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
Jensen LH; Nitiss KC; Rose A; Dong J; Zhou J; Hu T; Osheroff N; Jensen PB; Sehested M; Nitiss JL
J Biol Chem; 2000 Jan; 275(3):2137-46. PubMed ID: 10636919
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.
Cummings J; Sumner AT; Slavotinek A; Meikle I; Macpherson JS; Smyth JF
Mutat Res; 1995 Aug; 344(1-2):55-62. PubMed ID: 7565893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
